{
    "organizations": [],
    "uuid": "373bd5af053ff7a52121569583fa61dba9f1d2e8",
    "author": "",
    "url": "https://www.reuters.com/article/brief-progenics-pharmaceuticals-complete/brief-progenics-pharmaceuticals-completes-enrollment-in-phase-3-study-of-psma-targeted-imaging-agent-1404-idUSFWN1OX081",
    "ord_in_thread": 0,
    "title": "BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 2, 2018 / 1:46 PM / in 13 minutes BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404 Reuters Staff \nJan 2 (Reuters) - Progenics Pharmaceuticals Inc: * PROGENICS PHARMACEUTICALS INC - \n* PROGENICS PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PSMA-TARGETED IMAGING AGENT 1404 Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T15:46:00.000+02:00",
    "crawled": "2018-01-02T16:12:06.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "pharmaceutical",
        "completes",
        "enrollment",
        "phase",
        "study",
        "imaging",
        "agent",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "progenics",
        "pharmaceutical",
        "inc",
        "progenics",
        "pharmaceutical",
        "inc",
        "progenics",
        "pharmaceutical",
        "completes",
        "enrollment",
        "phase",
        "study",
        "imaging",
        "agent",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}